Neurodegenerative disease – Biasly

Neurodegenerative disease Follow

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap - Annovis Bio (NYSE:ANVS)

Neurodegenerative disease

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap - Annovis Bio (NYSE:ANVS)

Benzinga
Jul 24, 2024

Somewhat Liberal

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Neurodegenerative disease

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

Eagle-Tribune
Jul 24, 2024

Somewhat Liberal

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap - Annovis Bio (NYSE:ANVS)

Neurodegenerative disease

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap - Annovis Bio (NYSE:ANVS)

Benzinga
Jul 16, 2024

Somewhat Liberal

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development - Centogene (NASDAQ:CNTG)

Critical Path Institute

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development - Centogene (NASDAQ:CNTG)

Benzinga
Jun 20, 2024

Center

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

Critical Path Institute

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development

Eagle-Tribune
Jun 20, 2024

Center

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development By Investing.com

Multiomics

C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development By Investing.com

Investing
Jun 20, 2024

Center